Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Neogen Corporation (NASDAQ: NEOG) and certain of the Company’s senior executives for potential violations of the federal securities laws.

If you invested in Neogen, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/neogen-corporation-class-action-lawsuit.

Investors have until September 16, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Neogen stock. The case is pending in the U.S. District Court for the Western District of Michigan and is captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation, et al., No. 25-cv-00802.

Why Was Neogen Sued for Securities Fraud?

Neogen is a food safety company that manufactures and markets products and services dedicated to food and animal safety. In September 2022, Neogen merged with the Food Safety Division of the 3M Company (“3M”) in a $5.3 billion deal. During the relevant period, Neogen touted the integration process and stated the company made “huge strides” in 2024 that allowed the company to “refocus that energy and time from integration efforts to efficiency and growth efforts[.]”

In truth, as alleged, Neogen knew integration inefficiencies would necessitate a goodwill impairment and would impact capital expenditures, revenues, and EBITDA margins.

The Stock Declines as the Truth Is Revealed

On January 10, 2025, Neogen revealed that it was forced to take a $461 million non-cash goodwill impairment charge related to the 3M acquisition and cut its 2025 full year revenue and EBITDA guidance. On this news, the price of Neogen stock declined $0.71 per share, or over 5%, from a closing price of $13.07 per share on January 8, 2025, to $12.36 per share on January 10, 2025.

On April 9, 2025, the company again cut its fiscal year 2025 revenue and EBITDA outlook and announced an additional $100 million in capital expenditures as a result of lowered adjusted EBITDA and a pull-forward of integration-related capital expenditures. The company also revealed its CEO would be stepping down. On this news, the price of Neogen stock declined $2.02 per share, or over 28%, from a closing price of $7.04 per share on April 8, 2025, to $5.02 per share on April 9, 2025.

Then, on June 4, 2025, Neogen revealed that expected EBITDA would fall to “around the high-teens,” a significant decline from the prior quarter’s profit margin of 22% due to “elevated inventory write-offs.” On this news, the price of Neogen stock declined $1.04 per share, or over 17%, from a closing price of $6.00 per share on June 3, 2025, to $4.96 per share on June 4, 2025.

Click here for more information: https://www.bfalaw.com/cases-investigations/neogen-corporation-class-action-lawsuit.

What Can You Do?

If you invested in Neogen you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases-investigations/neogen-corporation-class-action-lawsuit

Or contact:

Ross Shikowitz

ross@bfalaw.com

212-789-3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases-investigations/neogen-corporation-class-action-lawsuit

Attorney advertising. Past results do not guarantee future outcomes.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250722725483/en/

Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Neogen Corporation (NASDAQ: NEOG) and certain of the Company’s senior executives for potential violations of the federal securities laws.